Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treprostinil Palmitil Inhalation Powder in PH-ILD
NCT07179380Phase 3Recruiting
- Sponsor
- Insmed Incorporated
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Inhalation Devices, Prodrugs/Conditional Activator Small Molecules
- Countries
- 30
01
Overview
A Phase 3 trial of treprostinil palmitil in Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD), sponsored by Insmed Incorporated. Started Jan 2026; status: recruiting.
02
Drugs
treprostinil palmitil
03
Conditions
Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD)
Beyond the preview
Go deeper on NCT07179380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07179380.